Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Researchers have uncovered a rare inherited mutation linked to prostate cancer—and it could help identify at-risk families ...

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...

Researchers at the University of British Columbia have identified a new form of hereditary prostate cancer that, while rare, ...

I was 18 when my mom was diagnosed with breast cancer. It altered the trajectory of my second year at college and changed how I viewed my mom, whom I naively thought was exempt from harm. She knew ...

Genetic testing can confirm a muscular dystrophy (MD) diagnosis when symptoms and other tests already suggest MD. It also identifies specific gene mutations that can guide targeted treatment. Genetic ...

We offer targeted detection of a previously characterized mutation within the family. From a fresh EDTA blood sample, DNA is extracted directly and the target region is amplified and directly ...

Eleven years after my mother died in 1994, when I was 31, I learned that a simple blood test could confirm whether I was a carrier of a BRCA gene mutation. Named for the first two letters of "breast" ...

Scientists at the Victor Chang Cardiac Research Institute have developed a world-first individualised risk prediction tool for people suffering from a type of heart arrhythmia that can cause sudden ...